Angiolite®
Sirolimus-Eluting Coronary Stent
The Angiolite® stent is engineered for high performance in real-world clinical scenarios, backed by long-term safety data.
Clinical Efficacy (Epic02 - RANGO Study)
-
5-Year Target Lesion Failure (TLF): Demonstrated a low rate of 8.7% in an all-comers, real-world population.
-
Safety Profile: Shows a remarkably low 5-year stent thrombosis rate of only 1.2%.
-
Performance in High-Risk Subgroups:
-
Diabetes: TLF of 11.1% at 5 years.
-
Small Vessel Disease (≤2.5 mm): TLF of 10.3% at 5 years with 0% stent thrombosis.
Mechanical & Biological Advantages
-
Rapid Endothelialization: The fluorinated polymer choice allows for significantly higher endothelial cell growth compared to control surfaces, reaching peak levels within 14 days to ensure quality healing.
-
Optimal Radial Force: Delivers superior arterial support with a radial force of approximately 0.121 N/mm, outperforming several major competitors.
-
Low Entry Profile: Features a very low entry profile of 0.016”, enhancing its ability to cross complex lesions.
